Van Dijck Ruben, Doorduijn Jeanette K, Bromberg Jacoline E C
Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Department of Neuro-Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Cancers (Basel). 2021 Apr 16;13(8):1920. doi: 10.3390/cancers13081920.
Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
原发性中枢神经系统淋巴瘤（PCNSL）是一种局限于中枢神经系统的非霍奇金淋巴瘤。其预后较差。对于新诊断患者采用以大剂量甲氨蝶呤为基础的化疗方案已达成共识，但添加单克隆抗CD20抗体利妥昔单抗是否能像在系统性B细胞非霍奇金淋巴瘤中那样提高生存率，仍存在争议。在本综述中，我们思考了利妥昔单抗在PCNSL中应用的现有证据。利妥昔单抗是否具有任何有益效果仍不确定。
